Mercosur Pharma Futures: Three Scenarios

Why Mercosur pharma matters now

Latin America’s pharmaceutical market is entering a more strategically relevant phase. Forecasts differ by source and methodology, but the direction is clear: the region is expected to grow, with Brazil remaining the dominant market and Argentina maintaining an important industrial role despite macroeconomic volatility.

Towards Healthcare estimates the Latin American pharmaceutical market at US$91.85 billion in 2024 and projects it to reach US$172.71 billion by 2034, with Brazil accounting for around 38 percent of the regional market. Americas Market Intelligence uses a broader logistics and healthcare-market framing and points to Latin America as one of the fastest-growing pharmaceutical regions globally.

For Econosur, the relevant point is not the exact number. The relevant point is the structure behind the number. Pharma demand is growing in a region where industrial capacity, regulation, imports, public health systems and distribution infrastructure remain uneven.

Brazil is the scale anchor

Any Mercosur pharma scenario begins with Brazil.

Sindusfarma reports that the Brazilian drug market traded BRL 178 billion in 2023, equivalent to US$35.6 billion, and describes Brazil as the leading pharmaceutical market in Latin America, ahead of Mexico, Colombia and Argentina. That scale gives Brazil a role that goes beyond domestic demand.

Brazil is also the regulatory heavyweight through ANVISA. For international firms, Brazil is often the key market that justifies serious regulatory, distribution and market-access work. For regional firms, Brazil is both an opportunity and a barrier: large enough to matter, but complex enough to require local knowledge, regulatory discipline and commercial patience.

This is why Brazil should not be treated as just another Mercosur member in pharmaceutical strategy. It is the anchor market that determines whether a regional pharma strategy has real scale.

Argentina is smaller, but strategically different

Argentina cannot match Brazil’s scale, but it has a different kind of relevance. It has a long pharmaceutical tradition, established local companies, export activity and a regulatory system that is currently changing in areas such as biosimilar comparability, OTC reclassification, import procedures and product traceability.

CILFA reported that Argentine medicine exports reached US$991 million in 2024 after growing 6.4 percent compared with 2023. INDEC’s pharmaceutical industry reporting continues to track national production, domestic sales and resale of imported products, showing that the sector is not only a healthcare-demand story but also an industrial and external-trade issue.

Argentina’s potential role is therefore not simply to become a larger consumer market. The more interesting scenario is whether it can position parts of its pharmaceutical base around generics, biosimilars, clinical trials, regulatory adaptation, regional exports and specialized production.

That possibility became more concrete in 2025 when ANMAT established requirements, guidelines and criteria for biosimilar comparability through Disposición 1741/2025. The rule does not automatically create a biosimilar hub. But it gives Argentina a clearer regulatory layer for one of the segments that could matter most in the next phase of regional pharmaceutical competition.

Paraguay and Uruguay show the smaller-market problem

Paraguay and Uruguay should not be ignored simply because they are smaller markets.

They show a different side of Mercosur pharma: smaller demand bases, higher exposure to imported medicines, more limited manufacturing depth and strong dependence on distribution, public procurement, affordability and regulatory access. These markets rarely define the region’s industrial future, but they matter for understanding how pharmaceutical products actually move through Mercosur.

The smaller-market problem is not only size. It is bargaining position. Brazil and Argentina can shape parts of the regional pharmaceutical conversation through scale, regulation or local industry. Paraguay and Uruguay usually have to solve a more practical question: how to secure reliable access to medicines, maintain quality standards and avoid being reduced to end markets served through external supply chains.

For companies, Paraguay and Uruguay can be entry, distribution or test markets. For policymakers, they raise a different question: how can smaller Mercosur economies improve access, supply security and regulatory efficiency without building the same industrial base as Brazil or Argentina?

This is where the regional logic becomes important. If Mercosur pharma remains fragmented, smaller markets stay exposed. If the region becomes more integrated, smaller markets could benefit from better regulatory recognition, more stable supply chains and broader regional production networks.

The EU-Mercosur agreement is a structural trigger

The EU-Mercosur agreement adds a new layer to the pharmaceutical discussion.

The Council of the European Union gave the green light for signature in January 2026, and the signing ceremony took place in Paraguay on 17 January 2026. The European Commission’s EU-Mercosur factsheet lists current Mercosur tariffs on pharmaceuticals at 14 percent and frames the agreement as a way to reduce high tariffs and create a more predictable trade environment.

For pharma, this does not mean that the region suddenly becomes one easy market. Tariffs are only one part of the access problem. Regulatory approval, reimbursement, public procurement, intellectual property rules, data protection, pharmacovigilance, distribution infrastructure and local representation remain decisive.

But lower tariffs and closer institutional cooperation can change the strategic calculation. European firms may look more seriously at Mercosur as a regional opportunity. Mercosur firms may seek better access to EU-facing standards, partners and distribution logic. Smaller companies in generics, specialty treatments, diagnostics, packaging, lab technology and regulatory services could find more precise entry points.

The hidden dependency: APIs and upstream inputs

Mercosur’s pharma future is also constrained by a global dependency that is often under-discussed in regional market narratives: active pharmaceutical ingredients, chemical intermediates, specialized equipment and upstream production inputs.

Latin America can expand formulation, packaging, quality control, distribution, clinical operations, generics and biosimilars. But full autonomy in APIs is a much harder industrial task. It requires scale, chemistry capabilities, environmental compliance, capital investment, supplier ecosystems and long-term procurement stability.

This is why a serious Mercosur pharma strategy has to separate three things: local medicine production, local API capacity and regional supply-chain resilience. They are related, but they are not the same.

A country can produce medicines locally while still depending heavily on imported APIs. A region can improve access to generics while remaining exposed to Asian supply shocks. A company can serve Mercosur commercially without having a deep manufacturing footprint in the region.

Scenario 1: Integration Accelerator

In this scenario, Brazil remains the anchor. Argentina becomes more relevant for selected production, biosimilars, clinical operations and export-oriented pharmaceutical activity. Paraguay and Uruguay benefit from improved supply access and more efficient regional distribution.

The companies most likely to benefit are not only large pharmaceutical multinationals. The opportunity also extends to mid-sized European firms, generics producers, specialized distributors, packaging companies, cold-chain operators, regulatory consultancies, lab equipment suppliers and quality-control service providers.

What would make this scenario more likely?

• Practical implementation of EU-Mercosur trade provisions.
• Stronger regulatory cooperation between European and Mercosur institutions.
• Clearer recognition pathways for selected products or processes.
• More regional production and distribution planning by pharmaceutical companies.
• Investment in cold chain, laboratories, packaging and quality infrastructure.

Scenario 2: Fragmentation Trap

This is the default risk. Mercosur has a regional identity, but pharmaceuticals are regulated through national systems. Brazil, Argentina, Paraguay and Uruguay do not offer the same market size, buyer structure, regulatory predictability or procurement environment.

For investors, the fragmentation scenario creates higher transaction costs. For exporters, it requires more local adaptation. For smaller countries, it can reinforce dependence on imports and distributors. For local firms, it can make regional expansion harder than the headline “Mercosur market” suggests.

What would make this scenario more likely?

• Slow or partial EU-Mercosur implementation.
• Persistent regulatory divergence across member states.
• Macroeconomic instability in Argentina or other markets.
• Weak regional recognition of standards and approvals.
• Distributor-dominated access without deeper industrial integration.

Scenario 3: Biosimilar Corridor

The biosimilar corridor scenario fits several signals. Brazil has market scale and regulatory weight. Argentina has local pharmaceutical companies, export history and new biosimilar comparability rules. Regional health systems face cost pressure, making generics and biosimilars strategically important. International firms also need partners who understand local access, regulation and distribution.

This scenario would not eliminate dependency on imported APIs or high-end technologies. But it could strengthen Mercosur’s position in formulation, comparability studies, quality systems, packaging, regional distribution, selected biological products and locally adapted therapeutic categories.

What would make this scenario more likely?

• Consistent implementation of biosimilar rules in Argentina.
• Brazilian demand for affordable biological and specialty treatments.
• Regional pressure to reduce healthcare costs.
• Investment by local champions and international partners.
• Better alignment between regulatory requirements, manufacturing quality and export ambitions.

The three scenarios are not mutually exclusive

The future will probably not fit one scenario perfectly.

Brazil may move ahead as a scale market while Argentina develops selected biosimilar and export capabilities. The EU-Mercosur agreement may reduce tariffs without removing all regulatory frictions. Paraguay and Uruguay may benefit from better access while still depending on imported products and distributor networks.

The more realistic reading is therefore layered: integration in some areas, fragmentation in others and corridor-building in specific segments such as generics, biosimilars, packaging, quality services and cold-chain logistics.

For companies, this means the right question is not “Is Mercosur one market?” The right question is: where is the region becoming more integrated, where is it still fragmented and where are specific pharmaceutical capabilities emerging?

Strategic implications for companies

For European pharmaceutical firms, the region should be read through a market-access lens, not just an export lens. Lower tariffs may improve the economics, but regulatory approval, local representation, product category, procurement channels and distribution reliability remain decisive.

For generics and biosimilar producers, Mercosur offers a demand story linked to affordability, public health pressure and rising treatment needs. But the opportunity depends on regulatory execution and the ability to compete against global suppliers with strong cost structures.

For B2B suppliers, the opportunity may be more immediate than for finished-drug manufacturers. Lab equipment, packaging, serialization, quality-control systems, cold-chain infrastructure, cleanroom technology, regulatory documentation, logistics and specialized consulting can all benefit from a more active pharmaceutical environment.

For investors and market analysts, the signal to watch is not only sales growth. It is the combination of regulation, trade access, local production, imports, public procurement and regional distribution.

What to watch next

Several signals will show which scenario is becoming more likely.

The first is implementation of the EU-Mercosur agreement. A signature changes expectations, but practical commercial impact depends on legal entry into force, tariff schedules, customs procedures and institutional follow-through.

The second is regulatory behavior. ANVISA and ANMAT matter because they shape the two most important pharmaceutical systems in Mercosur. Any move toward clearer recognition, faster procedures or more predictable technical requirements would change how firms approach the region.

The third is investment in industrial capability. If Brazil and Argentina attract investment in generics, biosimilars, packaging, quality systems, cold chain and clinical operations, the biosimilar corridor scenario becomes more plausible.

The fourth is import dependence. If API and finished-product dependence remains high, Mercosur may grow as a market without becoming meaningfully stronger as a production system.

Mercosur pharma is a market-structure story

Mercosur pharma should not be reduced to a growth forecast.

The region is growing, but growth alone does not define the opportunity. The more important story is how demand, regulation, industrial capacity and trade rules interact. Brazil gives the region scale. Argentina gives it a second industrial and regulatory pole. Paraguay and Uruguay reveal the access and dependency problem of smaller markets. The EU-Mercosur agreement creates a possible external trigger.

That is why the next phase should be read through scenarios.

If regulation and trade access improve, Mercosur pharma could become more integrated. If national frictions dominate, the region remains fragmented. If Brazil and Argentina build stronger generics and biosimilar capabilities, a more specific pharmaceutical corridor could emerge.

The market signal is clear: Mercosur pharma is no longer only a domestic health-sector issue. It is becoming a regional industrial, regulatory and trade question.